About The Event

Powered by latest developments with LNP CRISPR gene editing in the lungs, Bayer and Acuitas uniting to strengthen their Gene Therapy portfolio, new biotech ReNAgade Therapeutics launching with $300m Series A financing, lipid nanoparticles continue to dominate biopharma pipelines in 2024 and beyond as the most successful non-viral delivery vehicle to date. Moving into novel applications from gene therapy and cell therapy, and new disease indications from oncology to rare disease, LNP are equipping scientists with the ability to deliver transformative medicines to patients.